In the past year, China's biomedicine has developed rapidly, and innovative drugs have been produced frequently. Many biopharmaceutical companies have ushered in their first commercialized new drugs. The types of domestically approved drugs and the indications covered have gradually diversified. The first ADC drug independently developed by a Chinese local company, two CAR-T cell therapy drugs, and the first new crown neutralizing antibody combination therapy have been launched one after another. In the first half of 2022, domestic new drugs also achieved good results. The FDA approved a total of 16 new molecular entities/new biological products, and also approved 1 cell therapy and 1 vaccine. The scale of my country's drug R&D pipeline shows a trend of vigorous growth. As of August, there were 3,716 drugs (including Lisence-In) under active R&D process with R&D companies headquartered in mainland China. Cell therapy, gene therapy, nucleic acid drugs, double antibodies, ADC, upstream and downstream raw materials, synthetic biology, etc. are the focus of the biomedical market.
According to the National Bureau of Statistics, the market size of China's biopharmaceutical industry will exceed 4 trillion yuan in 2022. The government's "14th Five-Year Plan for Bio-Economy Development" ranks the bio-pharmaceutical industry at the top of the four key development areas. With the rapid development of biopharmaceuticals, the process of biopharmaceutical preparation has also been relatively perfected, but in the actual process of production, there is still a lot of room for improvement in terms of quality management and scientific development. In recent years, while supporting the development of the biopharmaceutical industry, the government has also introduced relevant policies to continuously strengthen the production process and quality supervision of biopharmaceuticals. Focusing on the future and facing the world, strengthening basic research and improving original innovation capabilities are the key to my country's biomedical innovation and upgrading.
Focusing on biomedical process development and quality science, committed to the technical exchange and development of the biomedical industry, promoting the innovation and industrial integration of China's biomedical scientific research forces, and further promoting the development of China's biomedical safety and pharmaceutical disciplines, the 3rd Asian Biomedical Innovation and Quality Technology Summit T-Bio 2023 hosted by Taas Labs will be held in Shanghai from January 5th to 6th . The summit lasted for 2 days , with 3 forums and technology exhibitions, respectively targeting core topics such as antibody drug process and quality science , ADC drug and nucleic acid drug process development and quality science , and cell therapy process and quality science . At that time, there will be 25+ industry experts to share experience insights and application cases, 30+ high-quality booths to display the latest technologies and solutions, 100+ global biotechnology and biomedical related companies will participate, and 500+ domestic and foreign participants will come to the site to discuss industry prospects and cooperation opportunities.
Some Hot Topics
☑ How can cell therapy products achieve rapid aseptic testing and rapid release?
☑ Experience sharing on quality requirements for IND declaration of cell products
☑ How to improve the druggability of antibody drugs through engineering technology and platforms?
☑ Anti-CTLA-4 fully human heavy chain antibody preparation experience and prospective flexible clinical trial quality management system
☑ Serum-free medium design and development for the production process of recombinant protein and virus vaccine
☑ One-stop vaccine development technology service solution
☑ Practical application case sharing of virus modular purification system
☑ Key quality attributes of ADC products
Some past speakers
Dr. Chen Shaoxiong Executive President and Secretary-General of Shanghai Biomedical Industry Association
Dr. Gong Likun Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Project Leader, Deputy Director of Drug Safety Evaluation and Research Center
Dr. Xinfang Li Myberry, Chief Operating Officer
Dr. Zhou Xinhua Jiahe Bio, Founder President Executive Director
Dr. Jijie Gu WuXi Biologics, Executive Vice President and Chief Scientific Officer
Dr. Huaqiong Shen I-Mab, Chief Executive Officer
Dr. Liao Shanmei BeiGene, Senior Director of Post-IPO Statistics
Mr. Li Shaochun IBM, General Manager of Watson Health in Greater China
Dr. Song Jun Novartis, Head of Business Development and Authorization of Novartis Biomedical Research Institute China
Mr. Qi He Gaocheng Biopharmaceuticals, Co-Founder and Chief Operating Officer
Dr. Wenkai Li Bojian, Head of Asia External Innovation
Dr. Dou Changlin Boan Biotechnology, Luye Group, Chief Operating Officer
Dr. Qi Xu Bibo Bio, Vice President
Dr. Xie Hongwei Xinda, expert in biopharmaceutical development and antibody characterization
Ms. Qingyao Zhou Tigermed, Senior Director of Registration
Mr. Yuan Qi Shanghai Zesheng Pharmaceutical, Director of Formulation Production
Mr. Zhang Ruliang Immune Onco, Deputy General Manager
Dr. Sheng Tu, Vice President
Dr. Jiang Wenzheng, East China Normal University, School of Life Sciences, Associate Dean Professor
Dr. Xie Xingwang Kerui Bio, Founder Chairman and CEO
Dr. Peng Shuangqing Medicilon Bio, Chief Scientific Officer
Dr. Shan Bo Antengene, Chief Scientific Officer
Dr. Zhiqiang Hu Huaaotai Biotech, Chief Medical Officer, Senior Deputy General Manager
Dr. Zhang Peizhuo, Chairman of Suzhou Gemma Gene Co., Ltd.
Dr. Jiang Qunfeng Innovent Bio, Director of Bioanalysis
Dr. Jiang Xinpo GenScript Biotechnology Co., Ltd., Assistant Vice President Reagent Product Development
Dr. Yang Naibo Huada Jinuoyin, Chief Operating Officer
Dr. Rolf G. Werner Bioinno Bio, Chairman of the Advisory Board
Past highlights
Part of the previous participating pharmaceutical companies
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai Biomedical Industry Association, Fudan University National University Science and Technology Park, Shanghai Pudong Fudan University Zhangjiang Institute of Science and Technology, Amgen, Biogen, BeiGene, Dongyao Pharmaceuticals, WuXi AppTec, Henlius, Sinopharm, Innovent Biologics, China Resources Double Crane, CStone Pharmaceuticals, Genome Biotech, Hengrui Medicine, Luye Group, WuXi Biologics, Merck, Merck, Chia Tai Tianqing, Nuocheng Jianhua, Novartis, Sunshine Guojian, Fosun Pharma, Harbor Biopharmaceuticals, Bangyao Biologics, CSPC, Fosun Kate, Boan Biotech, Gaocheng Biotech, Jiuyuan Genetics, Tigermed, Huada Genoin, China Resources Biological, Yangzijiang Pharmaceutical Group, Jemincare, Immune Onco, WuXi Biotech, Arnold, Crown Biotech, Junshi Biotech, Qilu Pharmaceuticals, Simcere Pharmaceuticals, IQVIA, Runze Biotech, Kangyuan Pharmaceuticals, Zesheng Pharmaceuticals, Zhongbangsirui, Dingfu Target, I-Mab Biotech, HUYA Biotech, Jiexin Pharmaceuticals Rui Biology, Qiuzhen Medicine, Watson Biology, Yingpai Pharmaceuticals, Quanxin Biology, Shengshi Junlian, Yisheng Biology, Cytiva, Hongbo Zhiyuan, Renhui Biology, Sartorius, etc...